Necrosis predicts benefit from hypoxia-modifying therapy in patients with high risk bladder cancer enrolled in a phase III randomised trial()

BACKGROUND AND PURPOSE: Addition of carbogen and nicotinamide (hypoxia-modifying agents) to radiotherapy improves the survival of patients with high risk bladder cancer. The study investigated whether histopathological tumour features and putative hypoxia markers predicted benefit from hypoxia modif...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Hoofdauteurs: Eustace, Amanda, Irlam, Joely J., Taylor, Janet, Denley, Helen, Agrawal, Shailesh, Choudhury, Ananya, Ryder, David, Ord, Jonathan J., Harris, Adrian L., Rojas, Ana M., Hoskin, Peter J., West, Catharine M.L.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Elsevier Scientific Publishers 2013
Onderwerpen:
Phase III randomised trial
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3885794/
https://ncbi.nlm.nih.gov/pubmed/23773411
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.radonc.2013.05.017
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items